CLINICAL_TRIALS
trial_result
· 2022-04-26
Clinical Trial Update: A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough [Phase 2]
Summary
Phase 2 dose-ranging study of Orvepitant in chronic refractory cough has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nerre Therapeutics Ltd. | Conditions: Chronic Refractory Cough | Phase 2 | Status: COMPLETED | Results posted: 2022-04-26